Literature DB >> 4597734

5-fluorocytosine resistance in Cryptococcus neoformans.

E R Block, A E Jennings, J E Bennett.   

Abstract

Isolates of Cryptococcus neoformans from six patients were obtained before and after unsuccessful therapy with 5-fluorocytosine (5-FC). Post-therapy isolates exhibited massive and stable 5-FC resistance. The frequency of drug-resistant mutants in susceptible isolates of C. neoformans was <0.001% (70.4 +/- 17.9 per 10(7) cryptococci), whereas mutant frequencies in resistant isolates approached 100%. Non-drug-induced, spontaneously appearing 5-FC resistant mutants were documented in four susceptible isolates of C. neoformans by use of the statistical method of fluctuation analysis. Mutation rates on these same four isolates ranged from 1.2 x 10(-7) to 4.8 x 10(-7). Total intracellular uptake and incorporation of cytosine-5-(3)H (CyH(3)) and 5-fluorocytosine-2-(14)C (5-FC(14)) into a trichloroacetic acid-insoluble fraction were markedly reduced in six isolates with in vivo-acquired resistance when compared with susceptible pretreatment strains from the same patients. Five of these six isolates also had acquired massive resistance to 5-fluorouracil (5-FU), suggesting that a mutation in the uridine-5'-monophosphate pyrophosphorylase was responsible for drug resistance. The sixth isolate, which remained susceptible to 5-FU, appeared to have a defect in a cytosine-specific permease accounting for 5-FC resistance. A single isolate with in vitro-acquired 5-FC and 5-FU resistance had no reduction in uptake or incorporation of CyH(3) or 5-FC(14). The mechanism of resistance in this isolate is discussed.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4597734      PMCID: PMC444474          DOI: 10.1128/AAC.3.6.649

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Isolation of Pre-Adaptive Mutants in Bacteria by Sib Selection.

Authors:  L L Cavalli-Sforza; J Lederberg
Journal:  Genetics       Date:  1956-05       Impact factor: 4.562

2.  Mutations of Bacteria from Virus Sensitivity to Virus Resistance.

Authors:  S E Luria; M Delbrück
Journal:  Genetics       Date:  1943-11       Impact factor: 4.562

3.  Bacterial resistance studies with derivatives of isonicotinic acid.

Authors:  W SZYBALSKI; V BRYSON
Journal:  Am Rev Tuberc       Date:  1952-06

4.  Genetic studies on the development of resistance to neomycin and dihydrostreptomycin in Myobacterium ranae.

Authors:  J Y HSIE; V BRYSON
Journal:  Am Rev Tuberc       Date:  1950-09

5.  5-fluorocytosine: an oral antifungal compound. A report on clinical and laboratory experience.

Authors:  P L Steer; M I Marks; P D Klite; T C Eickhoff
Journal:  Ann Intern Med       Date:  1972-01       Impact factor: 25.391

6.  5-Fluorocytosine in human cryptococcosis.

Authors:  J P Utz; B S Tynes; H J Shadomy; R J Duma; M M Kannan; K N Mason
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1968

7.  In vitro susceptibility of Cryptococcus neoformans to amphotericin B, hamycin, and 5-fluorocytosine.

Authors:  S Shadomy; H J Shadomy; J A McCay; J P Utz
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1968

8.  Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis.

Authors:  H L David
Journal:  Appl Microbiol       Date:  1970-11

9.  Genetic and physiological aspects of resistance to 5-fluoropyrimidines in Saccharomyces cerevisiae.

Authors:  R Jund; F Lacroute
Journal:  J Bacteriol       Date:  1970-06       Impact factor: 3.490

10.  Further in vitro studies with 5-fluorocytosine.

Authors:  S Shadomy
Journal:  Infect Immun       Date:  1970-10       Impact factor: 3.441

View more
  23 in total

1.  Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.

Authors:  Patrick Schwarz; Guilhem Janbon; Françoise Dromer; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

2.  History of medical mycology in the united states.

Authors:  A Espinel-Ingroff
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

3.  Cerebral cryptococcosis in Malaysia.

Authors:  P M Richardson; A Mohandas; N Arumugasamy
Journal:  J Neurol Neurosurg Psychiatry       Date:  1976-04       Impact factor: 10.154

4.  Auxotrophic mutants of Cryptococcus neoformans.

Authors:  E S Jacobson; D J Ayers
Journal:  J Bacteriol       Date:  1979-07       Impact factor: 3.490

5.  Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.

Authors:  A Espinel-Ingroff; A Chowdhary; M Cuenca-Estrella; A Fothergill; J Fuller; F Hagen; N Govender; J Guarro; E Johnson; C Lass-Flörl; S R Lockhart; M A Martins; J F Meis; M S C Melhem; L Ostrosky-Zeichner; T Pelaez; M A Pfaller; W A Schell; L Trilles; S Kidd; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

6.  In vitro and in vivo activity of 5-fluorocytosine on Acanthamoeba.

Authors:  A R Stevens; W D O'Dell
Journal:  Antimicrob Agents Chemother       Date:  1974-09       Impact factor: 5.191

7.  Cryptococcal meningitis.

Authors:  T L Tjia; Y K Yeow; C B Tan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-09       Impact factor: 10.154

8.  Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose.

Authors:  A Espinel-Ingroff; M Pfaller; M E Erwin; R N Jones
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

9.  Cryptococcosis after renal transplantation: report of ten cases.

Authors:  G P Schröter; D R Temple; B S Husberg; R Weil; T E Starzl
Journal:  Surgery       Date:  1976-03       Impact factor: 3.982

Review 10.  Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches.

Authors:  B D Alexander; J R Perfect
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.